Literature DB >> 20819089

Serum transforming growth factor β1 during diabetes development in non-obese diabetic mice and humans.

A Olivieri1, S De Angelis, S Dionisi, G D'Annunzio, M Locatelli, M Marinaro, V Bonato, A Amendola, M Songini, F Velluzzi, C Schirru, R Cotichini, M A Stazi, F Dotta, R Lorini, G F Bottazzo, M Boirivant.   

Abstract

Recent data show that regulatory cells with transforming growth factor (TGF)-β1-dependent activity are able to restore self-tolerance in overtly diabetic non-obese diabetic (NOD) mice. Thus, TGF-β1 seems to have a relevant role in protection from autoimmune diabetes. Our aim was to investigate the possible significance of serum TGF-β1 measurement in the natural history of diabetes in NOD mice, as well as in children positive for at least one islet-related antibody. Serum TGF-β1 (both total and active) was measured by enzyme-linked immunosorbent assay at monthly intervals in 26 NOD mice during the spontaneous development of diabetes and, on a yearly basis, in nine siblings of patients with type 1 diabetes (T1D) with a follow-up of 4 years. Diabetes appeared between the 12th week of age and the end of the study period (36 weeks) in 17 mice. TGF-β1 serum level variations occurred in the prediabetic period in both NOD mice and humans and diabetes diagnosis followed a continuing reduction of active TGF-β1 (aTGF-β1) serum levels. In mice, aTGF-β1 serum levels measured at 4 weeks of age correlated positively with severity of insulitis, and negatively with percentage of insulin-positive cells. Our findings suggest that in NOD mice serum TGF-β1 levels during the natural history of the diabetes reflect the course of islet inflammation. The measurement of aTGF-β1 in islet-related antibody-positive subjects may provide insights into the natural history of prediabetic phase of T1D.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20819089      PMCID: PMC3026544          DOI: 10.1111/j.1365-2249.2010.04253.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

Review 1.  Type 1 diabetes: recent developments.

Authors:  Devasenan Devendra; Edwin Liu; George S Eisenbarth
Journal:  BMJ       Date:  2004-03-27

2.  Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.

Authors:  Shelley Lindley; Colin M Dayan; Amanda Bishop; Bart O Roep; Mark Peakman; Timothy I M Tree
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

Review 3.  The NOD mouse: a model of immune dysregulation.

Authors:  Mark S Anderson; Jeffrey A Bluestone
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 4.  Activation of latent transforming growth factor beta.

Authors:  R Flaumenhaft; S Kojima; M Abe; D B Rifkin
Journal:  Adv Pharmacol       Date:  1993

5.  IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes.

Authors:  Ezio Bonifacio; Michael Hummel; Markus Walter; Sandra Schmid; Anette-G Ziegler
Journal:  Diabetes Care       Date:  2004-11       Impact factor: 19.112

6.  Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives.

Authors:  M R Pastore; E Bazzigaluppi; R Bonfanti; N Dozio; A Sergi; A Balini; C Belloni; F Meschi; E Bonifacio; E Bosi
Journal:  Diabetes Care       Date:  1998-09       Impact factor: 19.112

7.  Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus.

Authors:  A N Gorsuch; K M Spencer; J Lister; J M McNally; B M Dean; G F Bottazzo; A G Cudworth
Journal:  Lancet       Date:  1981 Dec 19-26       Impact factor: 79.321

8.  Type 1 diabetes among sardinian children is increasing: the Sardinian diabetes register for children aged 0-14 years (1989-1999).

Authors:  Anna Casu; Cristiana Pascutto; Luisa Bernardinelli; Marco Songini
Journal:  Diabetes Care       Date:  2004-07       Impact factor: 19.112

9.  Genetic prediction of type 1 diabetes in a population with low frequency of HLA risk genotypes and low incidence of the disease (the DIABFIN study).

Authors:  R Buzzetti; A Galgani; A Petrone; M L Del Buono; H A Erlich; T L Bugawan; R Lorini; F Meschi; G Multari; P Pozzilli; M Locatelli; G Bottazzo; U Di Mario
Journal:  Diabetes Metab Res Rev       Date:  2004 Mar-Apr       Impact factor: 4.876

10.  Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta 1.

Authors:  S C Wallick; I S Figari; R E Morris; A D Levinson; M A Palladino
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Targeting regulatory T cells in the treatment of type 1 diabetes mellitus.

Authors:  S M Cabrera; M R Rigby; R G Mirmira
Journal:  Curr Mol Med       Date:  2012-12       Impact factor: 2.222

Review 2.  Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes.

Authors:  Xia Wang; Peilin Zheng; Gan Huang; Lin Yang; Zhiguang Zhou
Journal:  Clin Exp Med       Date:  2018-07-17       Impact factor: 3.984

3.  Fasting and meal-stimulated residual beta cell function is positively associated with serum concentrations of proinflammatory cytokines and negatively associated with anti-inflammatory and regulatory cytokines in patients with longer term type 1 diabetes.

Authors:  M N Pham; H Kolb; T Battelino; J Ludvigsson; P Pozzilli; F Zivehe; M Roden; T Mandrup-Poulsen; N C Schloot
Journal:  Diabetologia       Date:  2013-03-15       Impact factor: 10.122

4.  Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1.

Authors:  Benjamin J Moyer; Itzel Y Rojas; Joanna S Kerley-Hamilton; Haley F Hazlett; Krishnamurthy V Nemani; Heidi W Trask; Rachel J West; Leslie E Lupien; Alan J Collins; Carol S Ringelberg; Barjor Gimi; William B Kinlaw; Craig R Tomlinson
Journal:  Toxicol Appl Pharmacol       Date:  2016-03-25       Impact factor: 4.219

5.  Deregulation of protein phosphatase 2A and hyperphosphorylation of τ protein following onset of diabetes in NOD mice.

Authors:  Marie-Amélie Papon; Noura B El Khoury; François Marcouiller; Carl Julien; Françoise Morin; Alexis Bretteville; Franck R Petry; Simon Gaudreau; Abdelaziz Amrani; Paul M Mathews; Sébastien S Hébert; Emmanuel Planel
Journal:  Diabetes       Date:  2012-09-06       Impact factor: 9.461

6.  Children who develop type 1 diabetes early in life show low levels of carnitine and amino acids at birth: does this finding shed light on the etiopathogenesis of the disease?

Authors:  G la Marca; S Malvagia; S Toni; B Piccini; V Di Ciommo; G F Bottazzo
Journal:  Nutr Diabetes       Date:  2013-10-28       Impact factor: 5.097

7.  Serum IL-17, IL-23, and TGF-β levels in type 1 and type 2 diabetic patients and age-matched healthy controls.

Authors:  Azam Roohi; Mina Tabrizi; Farzaneh Abbasi; Asal Ataie-Jafari; Behrouz Nikbin; Bagher Larijani; Mostafa Qorbani; Alipasha Meysamie; Hossein Asgarian-Omran; Bahram Nikmanesh; Arezou Bajouri; Novin Shafiey; Akram Maleki
Journal:  Biomed Res Int       Date:  2014-06-04       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.